Spondyloarthritis & psoriatic arthritis
Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial
Authors' conclusion
Our comprehensive set of circulating immune cell biomarkers showed no additional value in precision medicine, when added to clinical predictors.
Study context
- Population
- Patients with Psoriatic Arthritis (PsA), TOFA-PREDICT development cohort: DMARD-naïve patients and csDMARD inadequate respondersdevelopment cohort
- Participants
- 80 patients
- Comparison
- Tofacitinib vs MTX and tofacitinib vs etanercept
- Primary endpoint
- Added value of circulating immune cell biomarkers to a clinical model for predicting individual treatment response (Minimal Disease Activity)
- Follow-up
- Week 16
Methodological detailsbiomarker study, sparse partial least squares (sPLS) regression, extreme gradient boosting, Ridge regression
- Biomarker study
- sPLS regression
- Extreme gradient boosting
- Ridge regression
Primary result
As reported in the abstract
Prediction of individual treatment response, biomarker plus clinical data
Adding biomarker data to clinical data did not improve accuracy of individual response prediction (AUC-ROC)
0.74
Further findings
Variance in clinical manifestations explained by biomarkers
- Psoriasis severity, variance explained (up to)
- 27%
- Swollen joint count, variance explained (up to)
- 11%
Baseline biomarker profiles for treatment response
- Classified etanercept and MTX responders relatively well, but did not distinguish tofacitinib responders
Original publication
Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial. Arthritis Res Ther. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →